Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Outlook Disappoints | Global News Avenue

Moderna reported that the loss in the fourth quarter of Friday morning was greater than expected, and drugmakers’ 2025 sales forecast was also below estimates.

The Covid vaccine maker reported revenue in the last quarter of 2024 was $966 million, down 65% year-on-year, but in line with analyst expectations. But modernmRNAAccording to estimates compiled by Visible Alpha, the loss of $2.91 per share exceeded the $2.73 a share estimated by analysts.

“In 2025, we remain focused on driving sales until we offer up to 10 product approvals in 2027 and increase cost efficiency across the business,” CEO Stéphane Bancel said on Friday.

In September, the company Says planning By 2027, cut up to $1.1 billion in R&D costs by suspending or ending some early drug development to focus on winning current drug approvals in late-stage trials. Banker said the company expects to cut costs by about $1 billion by the end of this year, and said modernization “expected to recognize” new drugs multiple times starting in 2025.

Sales estimates are far below analyst consensus

Moderna said Friday it expects revenues of $1.5 billion to $2.5 billion in 2025, well below the analyst consensus of $3.26 billion. The drugmaker said it expects revenue of just $200 million in the first half of the year, “reflecting the seasonality of the respiratory business”, while analysts expect revenue of $207 million in the first quarter.

Entering 2025, Moderna has two products, namely its common vaccine and one vaccine that prevents respiratory disease RSV Among adults aged 60 and older. The company said it has recently submitted a request for approval for its “next generation” Covid vaccine, a combination vaccine for COVID and flu, and an “RSV vaccine for high-risk adults aged 18 to 59.”

Hyundai shares rose more than 4% on Friday morning, losing more than 60% of its value in the past 12 months.